BRPI0811200A2 - Tetra-hidrobenzapinas arilóxi- e heteroarilóxi-substituídas e uso das mesmas para bloquear percepção de norepinefrina, dopamina, e serotonina - Google Patents
Tetra-hidrobenzapinas arilóxi- e heteroarilóxi-substituídas e uso das mesmas para bloquear percepção de norepinefrina, dopamina, e serotoninaInfo
- Publication number
- BRPI0811200A2 BRPI0811200A2 BRPI0811200-2A2A BRPI0811200A BRPI0811200A2 BR PI0811200 A2 BRPI0811200 A2 BR PI0811200A2 BR PI0811200 A BRPI0811200 A BR PI0811200A BR PI0811200 A2 BRPI0811200 A2 BR PI0811200A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydrobenzapins
- serotonine
- norepinephrine
- dopamine
- aryloxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91720007P | 2007-05-10 | 2007-05-10 | |
PCT/US2008/063043 WO2008141082A1 (en) | 2007-05-10 | 2008-05-08 | Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0811200A2 true BRPI0811200A2 (pt) | 2014-10-29 |
BRPI0811200A8 BRPI0811200A8 (pt) | 2015-09-22 |
Family
ID=40002594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0811200A BRPI0811200A8 (pt) | 2007-05-10 | 2008-05-08 | Tetra-hidrobenzapinas arilóxi- e heteroarilóxi-substituídas e uso das mesmas para bloquear percepção de norepinefrina, dopamina, e serotonina |
Country Status (14)
Country | Link |
---|---|
US (1) | US8987252B2 (pt) |
EP (1) | EP2146720A4 (pt) |
JP (1) | JP5566282B2 (pt) |
KR (1) | KR20100017767A (pt) |
CN (1) | CN101686982A (pt) |
AU (1) | AU2008251558B2 (pt) |
BR (1) | BRPI0811200A8 (pt) |
CA (1) | CA2685861A1 (pt) |
CO (1) | CO6420345A2 (pt) |
EA (1) | EA017308B1 (pt) |
IL (1) | IL201923A0 (pt) |
MX (1) | MX2009011922A (pt) |
NZ (1) | NZ580802A (pt) |
WO (1) | WO2008141082A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101389246B1 (ko) | 2004-07-15 | 2014-04-24 | 브리스톨-마이어스스퀴브컴파니 | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
AU2010247735B2 (en) | 2009-05-12 | 2015-07-16 | Albany Molecular Research, Inc. | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof |
AU2010247763B2 (en) * | 2009-05-12 | 2015-12-24 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
JP2012526823A (ja) | 2009-05-12 | 2012-11-01 | アルバニー モレキュラー リサーチ, インコーポレイテッド | アリール、ヘテロアリール、および複素環置換テトラヒドロイソキノリンならびにそれらの使用 |
EP2606049A4 (en) | 2010-08-17 | 2014-01-08 | Albany Molecular Res Inc | 2,5-METHANO- AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USES THEREOF FOR BLOCKING NOREPINEPHRINE, DOPAMINE, AND SEROTONIN REUPTAKE |
CN103664974B (zh) * | 2012-09-17 | 2016-12-21 | 中国科学院上海药物研究所 | 芳基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用 |
PL2940008T3 (pl) * | 2012-12-26 | 2017-10-31 | Sanwa Kagaku Kenkyusho Co | Nowa pochodna benzoazepiny i jej zastosowanie farmaceutyczne |
WO2015161016A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Bicyclic cgrp receptor antagonists |
CN112209844A (zh) * | 2020-10-22 | 2021-01-12 | 上海吉奉生物科技有限公司 | 一种3-甲氨基丙酸的合成方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4988690A (en) | 1982-06-14 | 1991-01-29 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof |
JPS6394239A (ja) | 1986-10-08 | 1988-04-25 | Konica Corp | 色素画像の安定性を改良したハロゲン化銀写真感光材料 |
YU155791A (sh) | 1990-09-25 | 1994-01-20 | Agouron Pharmaceuticals Inc. | Antiproliferativna supstituisana triciklična jedinjenja |
US5202319A (en) | 1991-09-23 | 1993-04-13 | Hoechst-Roussel Pharmaceuticals Inc. | Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines |
US5416118A (en) | 1992-04-09 | 1995-05-16 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme A: cholesterol acyl transferase |
TW527355B (en) | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
HRP980443A2 (en) | 1997-08-18 | 1999-10-31 | Carl P. Decicco | Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis |
US6955873B1 (en) * | 2000-08-04 | 2005-10-18 | Kenneth Blum | Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors |
DE10028575A1 (de) | 2000-06-14 | 2002-03-14 | Basf Ag | Integrinliganden |
US6809092B2 (en) | 2000-01-26 | 2004-10-26 | Ono Pharmaceutical Co., Ltd. | Benezene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient |
TW200305423A (en) | 2002-02-14 | 2003-11-01 | Ono Pharmaceutical Co | N-carbamoyl nitrogen-containing condensed ring compound and medicament containing same as active ingredient |
GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
AU2004252150B2 (en) | 2003-06-26 | 2008-11-20 | Merck Sharp & Dohme Corp. | Benzodiazepine CGRP receptor antagonists |
EP1679309A4 (en) | 2003-10-24 | 2007-03-28 | Ono Pharmaceutical Co | ANTISTRESS MEDICAMENT AND ITS MEDICAL USE |
CA2559611C (en) | 2004-03-09 | 2012-01-17 | National Health Research Institutes | Pyrrolidine compounds |
US20060069086A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
KR101594898B1 (ko) * | 2005-07-15 | 2016-02-18 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
JP2011116663A (ja) | 2008-05-30 | 2011-06-16 | Otsuka Pharmaceut Co Ltd | ベンゾジアゼピン化合物 |
-
2008
- 2008-05-08 BR BRPI0811200A patent/BRPI0811200A8/pt not_active IP Right Cessation
- 2008-05-08 WO PCT/US2008/063043 patent/WO2008141082A1/en active Application Filing
- 2008-05-08 CA CA002685861A patent/CA2685861A1/en not_active Abandoned
- 2008-05-08 JP JP2010507655A patent/JP5566282B2/ja not_active Expired - Fee Related
- 2008-05-08 EP EP20080747852 patent/EP2146720A4/en not_active Withdrawn
- 2008-05-08 KR KR1020097025844A patent/KR20100017767A/ko not_active Application Discontinuation
- 2008-05-08 NZ NZ580802A patent/NZ580802A/xx not_active IP Right Cessation
- 2008-05-08 US US12/598,912 patent/US8987252B2/en not_active Expired - Fee Related
- 2008-05-08 MX MX2009011922A patent/MX2009011922A/es active IP Right Grant
- 2008-05-08 CN CN200880024102A patent/CN101686982A/zh active Pending
- 2008-05-08 AU AU2008251558A patent/AU2008251558B2/en not_active Ceased
- 2008-05-08 EA EA200971045A patent/EA017308B1/ru not_active IP Right Cessation
-
2009
- 2009-11-04 IL IL201923A patent/IL201923A0/en unknown
- 2009-12-10 CO CO09141201A patent/CO6420345A2/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CA2685861A1 (en) | 2008-11-20 |
CN101686982A (zh) | 2010-03-31 |
EP2146720A1 (en) | 2010-01-27 |
EA200971045A1 (ru) | 2010-06-30 |
MX2009011922A (es) | 2009-11-18 |
AU2008251558B2 (en) | 2012-12-20 |
CO6420345A2 (es) | 2012-04-16 |
NZ580802A (en) | 2012-09-28 |
JP5566282B2 (ja) | 2014-08-06 |
IL201923A0 (en) | 2010-06-16 |
US8987252B2 (en) | 2015-03-24 |
KR20100017767A (ko) | 2010-02-16 |
EA017308B1 (ru) | 2012-11-30 |
WO2008141082A1 (en) | 2008-11-20 |
US20100210624A1 (en) | 2010-08-19 |
BRPI0811200A8 (pt) | 2015-09-22 |
AU2008251558A1 (en) | 2008-11-20 |
EP2146720A4 (en) | 2012-01-18 |
JP2010527334A (ja) | 2010-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0811200A2 (pt) | Tetra-hidrobenzapinas arilóxi- e heteroarilóxi-substituídas e uso das mesmas para bloquear percepção de norepinefrina, dopamina, e serotonina | |
BRPI0822104A2 (pt) | Composições antimicrobianas e métodos para o uso das mesmas | |
BR112012002349A2 (pt) | composto,e, uso do mesmo | |
BR112012003792A2 (pt) | gel tópico, e, uso do gel tópico. | |
BRPI1013421A2 (pt) | composição parasticida tópica, e, uso de uma composição | |
BRPI0908792A2 (pt) | Composição, e, uso de uma combinação | |
BRPI1010775A2 (pt) | composição, método para preparar uma composição, e, uso de uma composição. | |
BRPI0911297A2 (pt) | composição e métodos para preparo e uso das mesmas | |
BRPI0811635A2 (pt) | Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos | |
BRPI0821668A2 (pt) | Uso | |
BRPI1014316A2 (pt) | composição, e, uso de uma composição | |
BRPI0813770A2 (pt) | Composição, e, uso de uma composição | |
BR112012005736A2 (pt) | di-hidro benzocicloalquiloximetil oxazolapirimidinonas substituídas, preparação e uso das mesmas | |
BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
BRPI0921995A2 (pt) | processo de deslocamento de gás para água , e, uso de um adsorvente. | |
BR112015000534A2 (pt) | método para a preparação de 2,4-dihidroxibutirato, microrganismo, organismo e uso | |
BR112013001423A2 (pt) | método, método in vitro, uso e kit útil para realizar o método | |
BRPI0914793A2 (pt) | Composição, e, uso de uma composição | |
BRPI0924184A2 (pt) | massas resistentes a ácidos, de consolidação hidráulica e o uso das mesmas | |
BRPI0918487A2 (pt) | processo para a preparação de uma composição de copolímero, composição, e, uso de uma composição de copolímero | |
BRPI0811204A2 (pt) | Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina. | |
BRPI1012250A2 (pt) | composição lubrificante, e, uso de uma composição lubrificante | |
BRPI1006996A2 (pt) | composição, método e uso | |
BRPI1008277A2 (pt) | composição de cloreto de sódio, processo para a preparação de uma composição de cloreto de sódio e uso de uma composição de cloreto de sódio não aglomerante | |
BRPI1015091A2 (pt) | novo uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: BRISTOL-MYERS SQUIBB COMPANY (US) , ALBANY MOLECUL |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |